CEL-SCI Announces Proposed Public Offering to Fund Cancer Immunotherapy Development

CEL-SCI Corporation is conducting a proposed public offering of common stock and/or pre-funded warrants. The offering is subject to market conditions and the company plans to use the net proceeds for Multikine development, general corporate purposes, and working capital. ThinkEquity is acting as the sole placement agent. The securities will be offered and sold pursuant to a shelf registration statement filed with the SEC. Interested parties can obtain a preliminary prospectus supplement and accompanying base prospectus from the SEC's website or ThinkEquity's offices.

CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, has announced its intention to offer to sell shares of its common stock (and/or pre-funded warrants) in a best-efforts public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering [1][2].

The company plans to use the net proceeds from this offering to fund the continued development of Multikine, for general corporate purposes, and working capital. ThinkEquity is acting as the sole placement agent for the offering. The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-288515), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 3, 2025 and declared effective on August 12, 2025. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying base prospectus describing the terms of the offering has been or will be filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying base prospectus relating to the offering may also be obtained from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying base prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering [1][2].

Multikine, a proprietary therapy designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland [1][2].

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected [1][2].

References:
[1] https://www.stocktitan.net/news/CVM/cel-sci-announces-proposed-public-2yas20jfe2nd.html
[2] https://www.marketscreener.com/news/cel-sci-announces-proposed-public-offering-ce7c50ded080f527